<DOC>
	<DOCNO>NCT01297582</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability ONO-6950 across ascend single dos healthy adult male female subject . The secondary objective characterize pharmacokinetic pharmacodynamic profile ONO-6950 measure plasma concentration ONO-6950 , pulmonary function , potential cardiovascular effect . The tertiary objective study evaluate effect meal upon pharmacokinetic profile ONO-6950 .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics ONO-6950 Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy nonsmoking male female subject ( 1855 inclusive ) Body mass index ( BMI ) 1935kg/m2 ( inclusive ) For female , postmenopausal , nonlactating , nonpregnant History presence clinical significant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-6950</keyword>
	<keyword>Healthy Adult Subjects</keyword>
</DOC>